The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the Moderna Spikevax Bivalent Original/Omicron BA.1 vaccine as a third and fourth dose in people aged 18 years and older.
This is the first bivalent COVID-19 vaccine approved for use in Australia, with the Therapeutic Goods Administration (TGA) the third regulator globally to approve this product.
The bivalent vaccine targets two different SARS-COV-2 viruses: the original 2020 strain and the Omicron variant BA.1.
Compared to the original vaccines, ATAGI found it triggers a modest improvement in the immune response against both strains. However, both the bivalent and original vaccines provide significant protection from severe disease against Omicron subvariant infections, an official press release said.
The first doses of the bivalent vaccine have arrived in the country and will now undergo batch testing by the TGA. They will be introduced into the rollout as existing stocks of the Moderna COVID-19 vaccine are exhausted.
View this post on Instagram
ATAGI has not made any changes to its current third and fourth dose recommendations and is not advising any extra doses at this time. You can find those recommendations here.
ATAGI continues to recommend that people who are due for a COVID-19 dose book an appointment, using whichever vaccine is available to them.
“This is an important first step in showing how mRNA vaccines can be adapted to different dominant variants and subvariants… All COVID-19 vaccines in our rollout continue to offer important protection against severe disease and the Moderna bivalent is another tool in Australia’s response to COVID-19,” Mark Butler, Minister for Health and Aged Care, said.
The Indian Sun acknowledges the support of the Victorian Government.
Support independent community journalism. Support The Indian Sun.
Follow The Indian Sun on Twitter | Instagram | Facebook
The Australian Govt has accepted a recommendation from the Australian Technical Advisory Group on Immunisation (ATAGI) on the use of the #Moderna Spikevax Bivalent Original/Omicron BA.1 #vaccine as a 3rd & 4th dose in people aged ≥18yo. #TheIndianSunhttps://t.co/qanADL9XMj
— The Indian Sun (@The_Indian_Sun) September 13, 2022
Donate To The Indian Sun
Dear Reader,The Indian Sun is an independent organisation committed to community journalism. We have, through the years, been able to reach a wide audience especially with the growth of social media, where we also have a strong presence. With platforms such as YouTube videos, we have been able to engage in different forms of storytelling. However, the past few years, like many media organisations around the world, it has not been an easy path. We have a greater challenge. We believe community journalism is very important for a multicultural country like Australia. We’re not able to do everything, but we aim for some of the most interesting stories and journalism of quality. We call upon readers like you to support us and make any contribution. Do make a DONATION NOW so we can continue with the volume and quality journalism that we are able to practice.
Thank you for your support.
Best wishes,
Team The Indian Sun
